Compass Therapeutics reports 2025 net loss of $66.5M; tovecimig PFS/OS data due in April

Compass Therapeutics, Inc.

Net loss $66.5M ($0.42/share) vs $49.4M ($0.36/share) in 2024; R&D spend up 32% to $56.0M.
Cash and marketable securities $209M as of Dec 31, 2025; expected runway into 2028.
Tovecimig COMPANION-002 PFS/OS analyses expected in April 2026 after reaching 80% OS events.
CTX-8371 expansion cohorts enrolling in TNBC and NSCLC; initial data expected Q2 2026.
CTX-10726 IND cleared; Phase 1 enrolling in Q1 2026; Bing Gong promoted to CSO.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Compass Therapeutics, Inc. reported year ended December 31, 2025 results: net income $66.5 million, EPS $0.42 per common share.

Period: year ended December 31, 2025
Net income: $66.5 million
EPS: $0.42 per common share
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2025, was $66.5 million or $0.42 per common share

View on SEC.gov

Browse all earnings releases →

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-001336

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.